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mmUCL Institute of Neurology, Department of Molecular Neuroscience, London, United KingdomAbstract Introduction: Cerebrospinal fluid collection by lumbar puncture (LP) is performed in the diagnostic
workup of several neurological brain diseases. Reluctance to perform the procedure is among others
due to a lack of standards and guidelines to minimize the risk of complications, such as post-LP head-
ache or back pain.
Methods: We provide consensus guidelines for the LP procedure to minimize the risk of complica-
tions. The recommendations are based on (1) data from a large multicenter LP feasibility study (ev-
idence level II-2), (2) systematic literature review on LP needle characteristics and post-LP
complications (evidence level II-2), (3) discussion of best practice within the Joint Programme
Neurodegenerative Disease Research Biomarkers for Alzheimer’s disease and Parkinson’s Disease
and Biomarkers for Multiple Sclerosis consortia (evidence level III).
Results: Our consensus guidelines address contraindications, as well as patient-related and
procedure-related risk factors that can influence the development of post-LP complications.
Discussion: When an LP is performed correctly, the procedure is well tolerated and accepted with a
low complication rate.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Lumbar puncture; Cerebrospinal fluid; Post-LP complications; Headache; Back pain; Consensus guidelines;Evidence-based guidelines1. Introduction
Lumbar puncture (LP) is a technique to sample cerebrospi-
nal fluid (CSF) as a window into brain pathology
(Supplemental Data). The procedure involves introducing a
needle into the subarachnoid space of the lumbar sac, at a level
safelybelow the spinal cord [1].Despitemodernneuroimaging
techniques, LP remains an important diagnostic tool as CSF
analysis provides important diagnostic information for many
neurological conditions. For example, no procedure can
replace the CSF analysis in differential diagnosis of infectious
disorders of the central nervous system (e.g., bacterial or viral
meningitis, neuroborreliosis). Moreover, CSF analysis is now
at the core of the diagnostic criteria for the diagnosis of Alz-
heimer’s disease [2–4]. In addition, an LP is the easiest
procedure to perform a CSF pressure measurement. Given
the use of CSF analysis for diagnosis, LPs are currently often
performed to perform research to discover novel diagnostic
biomarkers and understand brain pathology.
A recent large international, multicenter study on LP
feasibility that included 3868 patients in a memory clinic
setting showed that LPs can be safely performed [5]. Theacceptance rate of an LP was high, especially taking into
consideration that there was no acute medical indication.
The most common complications of LP consist of post-
LP back pain and post-LP headache (PLPH) [6]. PLPH
typically begins within three days after the procedure in
most patients [7]. If a patient develops typical PLPH, bed
rest, adequate hydration, and simple analgesics should be
started [8]. Further review of possible treatments will be
given in later sections of this study.
Very rare (prevalence of ,0.01%) but potential serious
complications consist of post-LP infections, spinal and
subdural cerebral hematoma, and cerebral venous thrombosis
[1]. In the multicenter LP feasibility study, a substantial
proportion (31%) of patients reported post-LP complaints;
however, thesewere mostly mild in nature, and severe compli-
cations were very rare [5]. Back pain, headache, and typical
PLPH were reported by 17%, 19%, and 9%, respectively
[5]. Only 0.3% of the patients needed a blood patch, and in
0.7%, a hospitalization was required [5]. The most important
risk factors for post-LP complaints were related to patient
characteristics: history of headache and fear of complications.
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related risk factor for typical PLPH. The number of LP
attempts was the only procedure-related risk factor for occur-
rence of local back pain. A large needle diameter (22G,
gauge [G]) was a risk factor for severe headache [5].
To date, consensus guidelines and recommendations for
the LP procedure to optimize diagnostic yield and to mini-
mize the risk of complications are lacking. We developed
consensus guidelines and recommendations for the LP
procedure based on the international multicenter LP feasi-
bility study outcomes combined with a literature-based anal-
ysis of risk factors. These guidelines will be applicable to
neurological brain diseases that require a diagnostic LP.
Moreover, these guidelines will serve to reduce complica-
tion rates in daily neurological practice, will be a reference
for educational purposes, thus be of help for trainees in
neurology, and will be a guide to comfort or give adequate
information to the patients.2. Materials and methods
These consensus guidelines originate from two interna-
tional consortia. The EU Joint Programme Neurodegenera-
tive Disease Research (JPND) consortium “Biomarkers for
Alzheimer’s disease (AD) and Parkinson’s Disease (PD)”
(BIOMARKAPD) aims at standardizing and harmonizing
existing biomarkers for AD and PD. The Biomarkers for
Multiple Sclerosis (BioMS) consortium aims at optimizing
all aspects of CSF biomarkers research for multiple sclerosis
and related disorders, via collaboration and developing
guidelines for relevant procedures. One of the objectives
of these consortia is to standardize and harmonize preanalyt-
ical procedures for CSF biomarkers that are used for or
contribute to diagnosis for neurological diseases. These pre-
analytical procedures include the LP procedure.
To provide consensus recommendations for the LP
procedure to optimize diagnostic yield and minimize the
risk of complications, three consecutive steps were used:
(1) data from the large multicenter LP feasibility study
[5],
(2) systematic literature review on LP needle character-
istics and post-LP complications,
(3) discussion within the JPND BIOMARKAPD (53
member centers) and BioMS (30 member centers)
consortia.
Our consensus guidelines address contraindications, as
well as patient-related and procedure-related risk factors
for the development of post-LP complications. Based on
U.S. preventive services task force [9], the level of evidence
of these recommendations is indicated. The level of evidence
was mostly level II-2 (well-designed cohort preferably with
more than one research group or center [e.g., data of large
multicenter LP feasibility study]) and level III (consensus
evidence based on clinical experience of the two consortia
involved [JPND BIOMARKAPD and BioMS]).2.1. Systematic literature review search strategy
As several studies have been published with regard to
the relation of LP needle characteristics and post-LP compli-
cations, we performed a systematic literature review,
covering relevant articles that have been published between
January 1970 and April 2016. Searches were conducted
through PubMed and Google Scholar. Only English articles
that contained needl* and lumbar punctur* in title and/or ab-
stract were taken into account [1]. In total, 307 articles were
found in the databases and screened/selected based on
PRISMA (Supplementary Material, Supplementary Fig. 1)
[10]. Case reports (n5 22), reviews (n5 29), articles about
animal models (n 5 6), and articles that not presented a
recommendation of a choice of needle were deselected
(n 5 187). Of the 63 remaining articles, statements
(n 5 3) and comments (n 5 7) about other publications
were deselected as well. Three “statement” articles pointed
out that atraumatic needles with a small-bore diameter
(24G) are not often used in practice although literature
often recommend using this type of needle [11–13]. Three
of the seven comments had no recommendation [14–16],
two agreed with the original article which recommended
atraumatic needles [17,18], one article agreed on small-
bore needles [19], and one article recommended small-
bore atraumatic needles [20]. In total, 53 fulfilled our criteria
and were subdivided into three groups. Articles that made
recommendations on needle design (n 5 24), the second
group consisted of articles with recommendations on needle
diameter (n 5 12), and the last group that did both (needle
design and diameter, n 5 17).
The 53 articles that did recommend a specific needle type
were graded based on the grade system described by Leone
et al. [21] (Supplementary Material, Supplementary
Table 1). Articles were classified as “low evidence” if they
had a total score (sum 5 limitations assets) of 25
(n 5 5), “medium evidence” articles if they had a score be-
tween 24 and 14 (n 5 21), and “high evidence” articles if
they had a score15 (n5 27). For an extensive description
of the grading approach, we refer to the Supplementary
Material.2.2. Selection of variables to become part of the consensus
guidelines
Based on the results of the multicenter LP feasibility
study [5] as well as on the systematic literature review [1],
the following variables were selected to provide consensus
guidelines:
 Conditions representing (potential) contraindications
for LP: the risk for cerebral herniation including
space-occupying lesion with mass effect, abnormal
intracranial pressure due to increased CSF pressure
and Arnold-Chiari malformation, increased bleeding
risk (thrombocytopenia, coagulopathies, anticoagulant
drugs), and local infections at the puncture site.
Table 1
Procedures to rule out contraindications for LP
Contraindication for LP Procedures to rule out contraindications Required action
1. Space-occupying lesion with mass
effect, increase of intracranial pressure
due to increased CSF pressure
2. Posterior fossa mass
3. Arnold-Chiari malformation
Clinical neurological examination
Fundoscopy
Perform brain CT/MRI scan if
- Abnormal clinical neurological
examination
- Papilledema
- (Patient has) reduced consciousness
- (Patient is) immune compromised
- (Patient has) previous CNS disease
- (Patient had) recent seizures
4. Anticoagulant medication Check medication before LP Can anticoagulants temporarily be
discontinued?
5. Coagulopathy
6. Uncorrected bleeding diathesis
Recent blood analysis: platelet
.40! 109/L; quick . 50%;
INR , 1.5
Correction possible?
7. Congenital spine abnormality Local inspection
Imaging in case of suspicion of
tethered cord
Guidance of LP procedure by fluoroscopy,
ultrasound, or CT
8. Skin infection at puncture site Local inspection Treat skin infection
Abbreviations: LP, lumbar puncture; CSF, cerebrospinal fluid; CT, computed tomography; MRI, magnetic resonance imaging; CNS, central nervous system;
INR, international normalized ratio.
NOTE. All recommendations are based on level-III evidence.
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for post-LP complications: age, gender, history of
headache, and fear of LP.
 Procedure-related factors that were associated with
increased risk for post-LP complications such as design
and diameter of the needle, number of LP attempts,
active versus passive withdrawal of CSF, reinsertion of
the stylet, positioning of the patient during LP, use of
local anesthetic, volume of CSF that was withdrawn
during LP, as well as bed rest after LP.
 Review of the possible treatments of PLPH.
2.3. Strategy to reach consensus
A first set of guidelines was designed based on the re-
sults of the international multicenter LP feasibility study
[5], available literature [1], and systematic literature re-
view. These were discussed during a JPND “BIO-
MARKAPD” general assembly, after which the
guidelines were further adapted (Mainz, Germany, spring
2014). A second version of the consensus guidelines was
drafted by S.E., E.N., H.S., F.D., and C.E.T. This draft
was e-mailed (July, 2014) to all participants of the JPND
“BIOMARKAPD” task force on standardization of preana-
lytical procedures, who were invited to provide their com-
ments and feedback. The prefinal draft was subsequently
mailed (November, 2014) with an invitation for feedback
to BioMS members and neurologists being key opinion
leaders in neurological disorders other than neurodegener-
ative brain diseases. The feedback and comments obtained
in this way was subsequently integrated which resulted in
the present consensus guidelines. This final version of the
consensus guidelines was again sent to all coauthors for
final approval.3. Results
3.1. Identification of LP contraindications
Contraindications were identified from the available litera-
ture. The most important contraindication for LP is an intracra-
nial space–occupying lesion with mass effect as well as a
posterior fossa mass because it can lead to herniation of the
cerebellar tonsils, regardless of the volume of CSF that is
sampled [22–26]. Other contraindications for LP include a
risk for cerebral herniation caused by abnormal intracranial
pressure due to increased CSF pressure or Arnold-Chiari mal-
formation, as well as anticoagulant medication, coagulopathies
and uncorrected bleeding diathesis, congenital spine abnormal-
ities, and local skin infection at the puncture site (Table 1).
Based on consensus (evidence level III); a brain computed
tomography or magnetic resonance imaging scan should at
least be performed before LP if an intracranial lesion with
mass effect, abnormal intracranial pressure due to increased
CSF pressure, or tonsillar herniation is suspected, or whenever
a patient has focal neurological deficits, is immune
compromised, has a previous central nervous system disease,
recent seizures, impaired consciousness, or papilledema at fun-
doscopy. The following imaging findings should be considered
as a contraindication for LP:
 Evidence for a pressure gradient across the falx cerebri.
Unequal supratentorial pressure gradients can result in
a lateral shift of midline structures. Asymmetry of
lateral ventricles is frequently a result of congenital
brain abnormality or congenital/perinatal stroke, pre-
senting an abnormal anatomical variant. On the other
hand, an asymmetry of the lateral ventricles should
not be considered to be an accurate sign, as ipsilateral
ventricular dilation may be caused by stroke and as
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anatomical variant. Performing an LP in patients
with unequal supratentorial pressure gradients can
result in compression of the ipsilateral temporal lobe,
leading to uncal herniation.
 Evidence for a pressure gradient between the supraten-
torial and infratentorial compartments.
Such pressure gradient may be caused by elevated
pressure above the tentorium cerebelli, and elevated
pressure below the tentorium cerebelli. Under these
circumstances, LP may lead to a bilateral uncal herni-
ation.
 Arnold-Chiari malformation. Patients with an Arnold-
Chiari malformation are prone to develop tonsillar
herniation, sometimes even after removal of small
volumes of CSF.
Brain and spinal hemorrhage and spinal epidural or
subdural hematoma are rare but potentially serious compli-
cations of an LP. For example, in the multicenter LP
feasibility study, only 1 of 3558 patients who underwent
LP experienced this side effect (leading to death after restart-
ing their oral anticoagulant) [5]. Therefore, it is advised
(level-III evidence) to have a recent analysis of the platelet
count (that should be .40! 109/L) and coagulation status
(quick.50%; international normalized ratio, 1.5). Coagu-
lopathies and uncorrected bleeding diathesis should be
absent. It is advised (level-III evidence) to discontinue anti-
coagulant treatments to minimize hemorrhagic risks. The
short-acting direct oral anticoagulants (DOACs) have as
advantage that they can be discontinued shortly before the
LP and that anticoagulation can be restarted within a few
hours (6–8 hours) after the procedure [27]. The decision pro-
cess should take into account the risk of discontinuation and
consequent risk of thrombosis, the possibility of bridging
with a low molecular weight or intravenous heparin (which
is not advised in case of DOACs), as well as the potential
benefit of the LP, and possible alternative examinations
(e.g., amyloid positron emission tomography instead of LP
to analyze AD biomarkers in CSF) [28]. Antiplatelet drugs
are only a relative contraindication, and most centers do
not interrupt treatment with antiplatelet drugs before LP.
Studies on LP complication risks in cases taking combina-
tions of antiplatelet drugs (e.g., clopidogrel and acetylsali-
cylic acid) are lacking, but it is considered safer to
temporarily withhold one of both before LP (level-III evi-
dence). In case of dual antiplatelet therapy, it is advised to
continue acetylsalicylic acid, whereas the intake of thieno-
pyridine derivatives (e.g., clopidogrel, ticlopidine) should
be temporally withhold (1 or 2 weeks) before LP unless pa-
tients are at high thrombotic risk or unless there is an urgent
indication to perform an LP (level-III evidence) [29].
Congenital spine abnormalities and spinal cord abnormal-
ities (e.g., tethered cord), or local skin infections at the LP
site can be contraindications to perform an LP. In case of
congenital spine abnormalities, the LP procedure can beguided by fluoroscopy, ultrasound, or computed tomography
[1,30–33]. Performing an LP through infected tissue
increases the risk of central nervous system infections and
reduces the diagnostic value of the LP in case of a
suspected central nervous system infection.
3.2. Patient-related risk factors
Data from the international multicenter LP feasibility
study indicate that patient characteristics are equally impor-
tant as LP procedure–related factors with regard to the risk
for post-LP complications (PLPH, post-LP back pain) [5].
Younger age is the most important and well-known risk
factor for PLPH and post-LP back pain [5,34,35]. Both
Monserrate et al. and the multicenter LP feasibility study,
including patients age 66 6 11 years, did not demonstrate
a gender difference [5,36], although it was repeatedly
reported that PLPH is more common in women than in
men, and especially women aged less than 40 years seem
to have a substantially higher risk of PLPH [7,34,35,37–
39]. Patients with history of headache had a higher risk to
develop PLPH and post-LP back pain (Figs. 1 and 2) [5].
Although age was accounted for, a diagnosis of mild cogni-
tive impairment or dementia was still associated with a risk
reduction of these post-LP complications in a memory clinic
setting. Although these patient-related risk factors for
post-LP complaints cannot be modified, these variables
can be of help to identify those patients that are at high
risk to develop post-LP complications. This information
can be used by physicians for counseling purposes (level
II-2 evidence).
In the multicenter LP feasibility study, it was shown that
fear of LP was an important independent risk factor for expe-
riencing post-LP complaints (Figs. 1 and 2) [5]. Hence, there
seems to be a psychological effect of anxiety relating to
more complaints, which might be explained by lack of infor-
mation beforehand, personality characteristics, or even a
nocebo effect of the LP [40]. As fear of the LP and post-
LP complications can be influenced by the attitude of the
physician and nursing staff and can be decreased by giving
reassuring but adequate information, it is of most importance
to carefully inform the patient. Moreover, although use of
local anesthesia is not related to reduced post-LP com-
plaints, it may help to control the fear of the LP procedure.
The physician should explain the procedure and should
outline the potential complications as well as the diagnostic
benefits from having an LP. Some of the patient-related risk
factors for post-LP complications can also be used to reas-
sure patients (e.g., when there is no history of headache,
patients are older or optimal needle type is used). During
the LP procedure, it is important to explain the different
steps of the LP procedure, thereby reducing eventual anxiety
and discomfort, meanwhile considering the eventual
cognitive deficits that affect memory and language compre-
hension, which requires a stepwise approach (level II-2 evi-
dence).
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Fig. 1. Risk factors for PLPH (A) and nonspecific headache (B) ranked by magnitude (defined by odds ratio) as reported by the multicenter LP feasibility study
[5]. Abbreviations: CI, confidence interval; LP, lumbar puncture; OR, odds ratio; PLPH, post-LP headache.
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3.3.1. LP procedure
Infection is a rare but potentially serious complication of
an LP. Therefore, also in an outpatient setting, an aseptic
technique should be applied using sterile gloves, and a thor-
ough disinfection of the lumbar region of the patient.
Furthermore, the physician can use a mask to minimize the
risk for infection. Excess of the antiseptic solution should
be removed from the skin before needle insertion (level-III
evidence). We refer to Fig. 3 for the LP procedure [1,41],
which holds true for both atraumatic and cutting bevel
needles [39,42,43].
During a minority of the LP procedures, nerve root irrita-
tion may occur [44]. The patient should be informed on fore-
hand that this may occur, albeit not dangerous, nor linked to
any complications (level-III evidence).
3.3.2. LP needle
The optimal needle length, diameter, and design should
be chosen when an LP is performed. This choice also
depends on the medical indication (e.g., LP as urgent
procedure in case of acute bacterial meningitis vs. an LP
to sample CSF to analyze AD biomarkers). Important vari-
ables are as follows: adequate flow rate, fast and accurate
transduction of CSF pressure, minimizing traumatic taps,
leakages, failures, and post-LP complications. LP needles
differ with regard to length, diameter, and design. The choiceof the needle depends on a patient’s age and weight, the pur-
pose of the LP procedure, and should be focused on mini-
mizing discomfort and risk for complications (Table 2).
Interestingly, the multicenter LP feasibility study showed
that effects of needle design and diameter were not as impor-
tant for post-LP complications as suggested by results of
previous studies (Figs. 1 and 2) [5]. Nevertheless, a cutting
bevel needle is a risk factor for typical PLPH (odds ratio
[OR] [95% Cl], 2.6 [1.3–5.0]) and a large-bore needle diam-
eter (22G) may be a risk factor for severe PLPH (OR [95%
Cl], 1.6 [0.9–2.7]) [5].
3.3.2.1. Length of the needle
In case of a dry tap (punctio sicca), the needle should be
advanced further to obtain CSF. Long spinal needles
(.90 mm) are used in patients with obesity. Nevertheless,
length of the needle is not the only factor that contributes
to a possible LP failure, experience of the operator is impor-
tant as well [45]. The procedure will be more difficult when
longer needles are used as these needles will be more flexible
and often divert off track during the procedure [46].
3.3.2.2. Diameter of the needle
Many considerations can be taken into account to decide
on needle gauge. Twenty-eight studies, published between
1970 and 2016 (references in this paragraph resulted from
the systematic literature review, Table 3), compared the
performance and complications of different diameters of
needles. No differences were detected in six studies
Fig. 3. Lumbar puncture procedure and position of the needle during a lum-
bar puncture. The procedure involves introducing a needle or its respective
introducer at the superior aspect of the inferior spinal process into the sub-
arachnoid space of the lumbar sac, at the L4/L5 level or other level safely
(L3/L4) below the spinal cord. The technique is for both atraumatic and cut-
ting bevel needles the same, but when using an atraumatic needle, an intro-
ducer is inserted into the interspinal ligament first, after which the smaller
atraumatic needle is inserted through the introducer. The introducer should
be inserted no more than 2/3 – 1/4 of the total length, depending on the adi-
pose tissue availability. During the procedure, the needle stylet is removed
every 2-mminterval to check for flowofCSF. In case a nonrecommended cut-
ting bevel needle is used, it is preferred to hold the bevel in the sagittal plane
as this diminishes injury to the duramater by separating its longitudinal fibers
rather than cutting through them and reduces the risk of leakage of CSF after
the LP. Abbreviations: CSF, cerebrospinal fluid; LP, lumbar puncture.
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study concluded that needles with a larger diameter (22G)
had a positive effect on collection time and resulted in less
failures [53]. The LP feasibility study performed in memoryTable 2
Needle characteristics are compared based on needle length, size, and design (sys
Needle Comparison Advantages
Length Regular (70–90 mm) Adults
Long (.90 mm) Obesity
Diameter in gauge Small (24G) Reduced complication r
Reduced pain and disco
Decreased risk factor: b
Requires less medical a
medications
Large (22G) Increased flow rates
Decreased sampling tim
Fewer failures
Design Cutting bevel Penetration is felt throu
Atraumatic Reduced complication r
Reduced medical health
post-LP complication
assistance, and medi
Decreased traumatic tap
Abbreviation: G, gauge.clinic settings did not show that large-bore diameter needles
confer independent risk compared with small bore needle
types. However, smaller bore needles (defined as 24G)
are recommended by most studies [5,36,38,54–71], based
on lower incidence of PLPH, back pain, and discomfort. A
lower incidence of complications resulted in less medical
assistance and less medication after the procedure.
Small-bore needles result in less blood contamination
(.5/mL red blood cells in the first tube of CSF collected)
[34]. Advantages of large-bore spinal needles are a faster
CSF flow (e.g., when large volumes of CSF should be
collected like in case of an evacuating LP), and a shorter
time needed to equilibrate CSF pressure, when a manometer
is used. For CSF, pressure measurement needles that are
smaller than 22G (thus .22G) are not suitable. Moreover,
the smallest needle types (27G-29G) are not recommended
because more technical difficulties occur, which might result
in more failures, and due to the prolonged duration of the LP
procedure [72]. On the other hand, large-bore needles
(22G) are not recommended as they result in large dural
perforations and increased risk of post-LP complications
and blood contaminations [56,62].
On the basis of the systematic literature analysis (level II-
2 evidence), a balance between risk of PLPH, procedure
duration, and technical failure has to be considered for
each individual patient when choosing for a specific needle
type. In daily clinical practice, a 22G or larger diameter
(,22G) needles are most often used [73,74]. Moreover,
because there was no risk with large needles in the LP
feasibility study, this needle can be chosen in memory
clinics. Once the practitioner is more confident, by a more
frequent usage, small-bore needles should be considered in
other populations, which can then be used with a small
number of failures [39,75].tematic literature review 2016 [1])
Disadvantages
—
Challenging approach
ates
mfort
lood contaminations
ssistance and
Decreased flow rates, increased sampling
times
More failures
Requires training and practice
es
Increased complication rates
Perforations are larger
Increased risk factor: contaminations
gh skin Increased complication rates. Requires more
use of medications and medical assistance,
which results in increased costs.
ates
care costs due to less
s, medical
cations
s
Decreased flow rates, increased sampling
times
Increased amount of attempts and failures
Penetration through skin is difficult to feel
Table 3
Needle diameters compared through a systematic literature review [1]
Conclusions Diameters of needles compared Motivations References
No difference: in needle diameters 20G versus 22G No difference: PLPH, complaints, traumatic
tap incidence, CSF pressure measurement
[47–49]
22G versus 25G No difference: PLPH, complaints, attempts [50,51]
23G versus 25G No difference: PLPH, low back pain,
attempts
[52]
Favors: large-bore diameters 20G versus 22G versus 24G versus 25G Reduced: collection times
Faster: CSF pressure measurement
[53]
Favors: small-diameter bores 18G versus 20G versus 22G versus 24G
versus 25G
Lower frequency: PLPH [54]
18G versus 20G versus 22G versus 24G
versus 25G versus 26G versus 27G
Reduced: collection times
Faster: CSF pressure measurement
[55]
19G versus 20G versus 22G
22 G versus 25G versus 27G
Lower frequency: PLPH [56]
20G versus 22G Lower frequency: PLPH, complaints, blood
patch rates
Increased: collection times
[57–61]
20G versus 22G versus 23G Lower frequency: PLPH [62]
20G versus 22G versus 25G Lower frequency: PLPH
Increased: collection times
More: practice, failures
[63]
20G versus 24G
20 G versus 23G versus 25G versus 26G
Lower frequency: PLPH [36]
22G versus 24G Lower frequency: PLPH, complaints [64]
22G versus 25G Lower frequency: PLPH, low back pain,
complaints
Reduced: costs (health care)
Lower frequency: leakage
[65–67]
22G versus 26G Lower frequency: PLPH, pain
More: practice
[38,68,69]
22G versus 29G Lower frequency: PLPH,
Reduced: failures
[70]
25G versus 26G versus 27G Lower frequency: PLPH
Reduced: blood patch rates
[71]
Abbreviations: G, gauge; PLPH, postlumbar puncture headache; CSF, cerebrospinal fluid.
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Different needle designs are available. Cutting bevel
needles (standard Quincke [76] and Yale) are the standard
needles with a medium cutting bevel and an orifice at the nee-
dle tip. Atraucan, Pecan, Sprotte, and Whitacre needles are
noncutting, pencil-point, and atraumatic needles (Fig. 4). Me-
dium (23G-24G) cutting bevel needles are most frequentlyFig. 4. Schematic representative of lateral (A) and superior (B) aspects of the tips
bore beveled needle; and 3, atraumatic small-bore needle.used in clinical practice. As most atraumatic needles have
smaller bores, these needles are associated with the same dis-
advantages of small-bore needles described previously
[34,35,39,73–75,77,78].
Thirty-seven studies, published from 1970 till 2016,
compared needle designs (all references in the following
paragraphs are based on the systematic literature review,of spinal needles: 1, standard large-bore beveled needle; 2, standard small-
Table 4
Needle designs compared through a systematic literature review [1]
Conclusion Needle designs compared Motivations Comments References
Favors: atraumatic needle Quincke versus Pencan Lower frequency: PLPH,
low back pain
Reduced: PLPH interval [66]
Quincke versus Pencan Lower frequency: PLPH,
post-LP complaints
Reduced: costs
[67]
Quincke versus Sprotte Lower frequency: PLPH,
post-LP complaints,
nausea/vomiting
Reduced: costs (health care)
due to less medications
and medical assistance
Reduced: traumatic taps
More: training
Availability of atraumatic
is less
Same concentrations of IgM
in CSF and serum
Training increases the confidence
of handling atraumatic needles
[49,57,75,79–85]
Quincke versus Sprotte Lower frequency: PLPH
Increased: failure rates
[86]
Quincke versus Sprotte
versus Whitacre
Lower frequency: PLPH Fewer cells attached to needle
(size of cells are smaller),
minor epithelial cells
[63,87,88]
Quincke versus Sprotte
versus Whitacre
Lower frequency: PLPH [53]
Quincke versus Whitacre Lower frequency: PLPH,
post-LP complaints
Reduced: blood patch rates
Lower frequency: leakage
[48,60,65,71,89–91]
Questionnaire to medical
institutions. Favors:
atraumatic needle
Quincke versus Sprotte Lower frequency: PLPH
More: practice, training
Increased: costs (needles)
[73,75]
Quincke versus Sprotte
versus Whitacre
Lower frequency: PLPH
Reduced: costs (health care)
More: practice, training
[92]
No difference: in needle
designs
Quincke versus Sprotte
versus Whitacre
No difference: flow
properties
No influence of the performance
of needle designs (on flow
properties)
[55]
Quincke versus
Whitacre
No difference: PLPH, low
back pain
Same incidence (of PLPH and low
back pain) for both needle
designs
[93,94]
Quincke versus
Whitacre
No difference: counts in
RBC, leakage
[95]
Yale versus Pencan No difference: success rates No influence of the performance
of needle designs (on success
rates in children)
[96]
Yale versus Sprotte No difference: PLPH,
traumatic taps
Same incidence (of PLPH and
traumatic tap) for both needle
designs
[97]
Abbreviations: PLPH, postlumbar puncture headache; LP, lumbar puncture; CSF, cerebrospinal fluid; RBC, red blood cell.
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gard to incidence of traumatic tap of vascular structures,
procedure time and success rate in children, through com-
parison of transdural fluid leakage and vascular trauma
associated with blood contamination in CSF (Pencan vs.
Yale, Quincke vs. Yale, Whitacre vs. Quincke) [93,95–
97]. One study investigated the incidence of PLPH and
low back pain and did not reveal any difference
(Whitacre vs. Quincke) [94]. Two studies compared the
flow rates and reported no significant differences for both
needle designs (atraumatic vs. cutting bevel needles, Whi-
tacre vs. Sprotte vs. Quincke) [55,98].However, atraumatic needles are recommended by most of
the 37 articles as the best needle to perform LPs. Indeed,
when comparing different needle designs, atraumatic needles
resulted in a lower prevalence of post-LP complaints, including
PLPH, low back pain or nausea/vomiting (Table 4)
[5,36,48,49,53,54,57,58,60,61,63–67,71,75,79–91]. A lower
frequency of complications results in reduced health care
costs due to less medication or medical assistance, such
as blood patches [48,49,53,54,57,61,64,66,75,79–84,86–
91,93,96]. A lower incidence of traumatic taps has been
reported when using atraumatic needles. However, atraumatic
needles result in more attempts and failures [86]. No data are
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number of traumatic taps, attempts, or failures. The technical
drawbacks of atraumatic needles can be overcome with more
training. Therefore, we conclude that the disadvantages are
less decisive compared with the reduced risk of PLPH, which
results in the time and cost savings for the health care system
and less discomfort for the patient [11,81,82,92,99,100].
In summary, head-to-head studies are in favor of atrau-
matic type needles with regard to the lower incidence of
PLPH (level II-2 evidence).
3.3.3. Number of LP attempts
In case of an unsuccessful attempt, the needle (in case of
cutting bevel needle) or the guide (in case of atraumatic
needle) has to be withdrawn partially to the subcutaneous
tissue and has to be reangled [101]. If the attempt is still
unsuccessful, repalpation should reassure that the needle is
in the midline. Multiple attempts may lead to local swelling
and/or bruising as well as muscle spasms and is therefore
associated with a higher risk for back pain [5]. Furthermore,
it will obscure surface anatomical landmarks, making future
attempts technically more difficult [46].
The number of LP attempts was significantly associated
with post-LP back pain (Fig. 2) [5]. In case of 2–4 attempts,
the OR [95% CI] was 2.1 [1.7–2.7], whereas in case of 5
attempts, the OR [95% Cl] increased to 5.4 [2.9–10.2] [5].
A total of four attempts is regarded as an acceptable
maximum (level II-2 evidence).
3.3.4. Active versus passive withdrawal of CSF
Active withdrawal obviously reduces the procedural time,
especiallywith small-bore needles, but thismay be less impor-
tant than the higher risk of PLPH. Passive withdrawal of CSF
resulted in a lower risk for nonspecific headache (OR [95%
Cl] 0.68 [0.50–0.92]), and a strongly lower risk for severe
headache (OR [95% CI] 0.52 [0.33–0.84]) [5]. In addition,
using a syringe results in negative pressure and might cause
subdural hemorrhage or herniation or might result in pares-
thesia, pain, or injury in case a spinal nerve root was pulled,
although these complications occur rarely. Active CSF with-
drawal using a syringe, in combination with an adequate nee-
dle diameter, is often performed in the course of collection of
large volumes for research purposes, but should only be per-
formed when a long procedure is not appropriate for the
patient or clinical setting (level II-2 evidence).
3.3.5. Other LP-related factors
An LP can be performed with the patient in the lateral
recumbent position, also known as supine position, or in
sitting position. In the lateral recumbent position, the patient
should be positioned with knees-to-chest and with the back
flexed as far as possible toward the physician performing
the LP, and the coronal plane of the trunk should be perpen-
dicular to the floor with one hip exactly above the other. In
this position, lumbar lordosis is overcome and the neck is in
a neutral position. The needle should stay in the midline ofthe spine, and therefore, it is placed parallel to the floor. In
the sitting position, the patient completely flexes neck and
back as this facilitates the course of the needle by widening
the gap between adjacent lumbar spinal processes. The
preferred position depends on the physician and on the
patient’s clinical conditions (level-III evidence). In case of
immobilized patients and/or patients being unable to sit up,
the lateral recumbent position should be applied. This posi-
tion may be included in the clinical training/practice of resi-
dents, to be familiar with the procedure. For CSF pressure
measurement, patients need to be in the lateral recumbent po-
sition [101,102]. The sitting position has the advantage of a
higher CSF pressure and flow, which reduces the sampling
time. In the multicenter LP feasibility study, positioning of
the patient was not associated with PLPH or post-LP back
pain [5]. However, additional analysis showed that sitting po-
sition during LP procedure appeared to be a risk factor for
severe headache, not for typical PLPH. Monserrate et al.
mentioned also a trend for developing headache after LP in
the sitting position [36].
When using an atraumatic needle, it is recommended to
reinsert the stylet to the tip of the needle before removing
the needle as this was associated with a lower prevalence
of PLPH [103].
In the multicenter LP feasibility study, local anesthesia
was used in 41% of the patients, mostly when the LP was
performed with a large-bore diameter needle [5]. The appli-
cation of local anesthesia or not was not associated with
post-LP complaints. In addition, bed rest after LP and the
volume of CSF withdrawn (up to 12 mL and more) were
not associated with change in prevalence of PLPH or post-
LP back pain [5]. Therefore, there is no recommendation
to apply local anesthesia and bed rest after the LP to reduce
postpuncture complaints. Collection of up to 30 mL of CSF
is well tolerated and safe [36] and is advised as an acceptable
maximum. Nevertheless, other LP procedure–related factors
should depend on patient’s-related, physician-related, and/or
clinical setting–related factors (level II-2 evidence). For
example, very small needle bores will extend the collection
time for this volume.3.4. Treatment of PLPH
More than 85% of PLPH will resolve without any other
specific treatment [104]. The only evidence-based treatment
for typical severe PLPH (severe usually frontal headache
possibly accompanied by nausea and vomiting which is
relieved by recumbent posture) is an epidural blood patch
[105]. The most efficient volume of blood appears to be
20–30 mL [104]. This procedure has a success rate of
70%–98% if carried out more than 24 hours after the LP
[104]. If a first epidural blood patch fails to resolve the head-
ache, repeating the procedure has a similar success rate
[104]. There is a lack of evidence to recommend pharmaco-
logical treatments of typical PLPH [106]. The few random-
ized clinical trials that have been performed included a
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postpartum women in their 30s, limiting the generalizability
[106]. Taking into account these limitations, caffeine
decreased the proportion of subjects with persisting PLPH
and the subjects requiring supplementary interventions
compared with placebo [106]. Gabapentin, hydrocortisone,
and theophylline decreased pain severity scores [106].4. Conclusions: Recommendations
Based on the results of the international, multicenter LP
feasibility study, literature-based analysis of risk factors,
and best clinical practices discussed in the previous sections,
we formulate the following consensus guidelines and recom-
mendations for the LP procedure in adults. These recom-
mendations should minimize post-LP complications, the
most frequent being PLPH and post-LP back pain. The
recommendations are summarized in Box 1 and Table 5.
As these are guidelines, every professional can adapt the
guidelines based on their own experience and based on the
patient’s comfort and benefits. We refer to the last article
in a series of four articles on issues in the development
and use of clinical guidelines, which focuses on how clinical
guidelines should be used, in health care settings but also by
an individual clinician [107].
First, contraindications for LP should be ruled out
(Table 1). The following recommendations are consensus
based (level-III evidence).
 It is advised to perform brain imaging before LP, when-
ever an intracranial lesion with mass effect, abnormal
intracranial pressure due to increased CSF pressure, or
tonsillar herniation is suspected based on medical his-
tory or neurological examination, and in case of recent
seizures, impaired consciousness, or papilledema.
 Coagulation status and platelet count (should be higher
than 40! 109/L) should be checked by (recent) blood
analysis before LP.Box 1
Recommendations to minimize post-LP complaints and complications (All
Patient-related characteristics with regard to post-LP complaint
 Risk factors: younger age, being female,40 years old, prev
 Less risk: cognitive deterioration
/ Serve to identify patients that are at high risk to devel
/ Serve to inform and reassure patients, before and duri
LP procedure:
 Use 25G atraumatic needles
 Not more than four LP attempts
 Passive withdrawal of CSF
 Collection of up to 30 mL of CSF is well tolerated and sa
 Lateral recumbent position
No influence of local anesthesia and bed rest after LP.
Abbreviations: CSF, cerebrospinal fluid; G, gauge; LP, lumbar p Concomitant medication should be checked before LP.
In case of intake of anticoagulants, an LP is contraindi-
cated unless the risk of the procedure outweighs the
potential benefit. Direct acting anticoagulants can be
temporarily interrupted. An LP can be performed
without substantial risk when patients take one type
of antiplatelet drug.
 Infections at the LP site are relative contraindications.
As patient-related characteristics are among the most
important risk factors for PLPH and post-LP back pain, the
physician should determine the risk profile of the patient.
Although the patient-related risk factors cannot be modified,
these can be of help to identify those patients that are at high
risk to develop post-LP complaints. Moreover, as fear of com-
plications is an important risk factor for post-LP complaints,
the patient should be informed thoroughly and should be re-
assured, before and during the LP procedure (level-III evi-
dence). Recommended based on level II-2 and III evidence:
 Younger age, being a female aged less than 40 years, pre-
vious history of headache, and fear of post-LP complica-
tions are risk factors for PLPH and post-LP back pain.
 Post-LP complaints are less prevalent in patients with
cognitive deterioration [5].
Recommendations with regard to the LP procedure itself
are based on level II-2 and III evidence:
 It is recommended to use 25G atraumatic needles given
the reduced incidence of PLPH.
 A total of four attempts may be regarded as an accept-
able maximum, as the risk for back pain significantly
increased with more than 4 attempts [5].
 Active CSF withdrawal using a syringe should only be
performed when a patient cannot tolerate a long pro-
cedure. If a large volume of CSF has to be withdrawn
(e.g., for research purposes or in case of an evacuating
LP), a larger needle diameter is recommended instead
of active withdrawal by using a syringe.recommendations are at least level II evidence, type 2)
s and complications:
ious history of headache, and fear of post-LP complications
op post-LP complaints
ng the LP procedure
fe
uncture.
Table 5
Recommendations based on level II-2 and III evidence described by graded risk factors
Recommended procedure Risk factors Grading risk factors Level of evidence
Rule out contraindications
1. Brain imaging before LP, in case of
- an intracranial lesion with mass
effect,
- abnormal intracranial pressure,
- tonsillar herniation is suspected
(based on medical history or
neurological examination),
- recent seizures,
- impaired consciousness,
- papilledema
2 III
2. Check platelet and coagulation status:
platelet .40! 109/L; quick .50%;
INR ,1.5
Coagulopathy
Uncorrected bleeding diathesis
1/2
2
III
III
3. Check medication before LP Anticoagulant medication 1/2 III
Patients-related risk factors:
1. Determine risk profile and inform and
reassure patients before and during LP
procedure
Risk factors
1. Younger age PLPH, back pain 11 II-2, III
2. Being female ,40 years old Post-LP complaints 1/2 III
3. History of headache PLPH, back pain 11 II-2
4. Fear of post-LP complaints Post-LP complaints 1 II-2
Less risk
1. Cognitive deterioration PLPH, back pain 1 II-2, III
Procedure-related risk factors
1. 25G atraumatic needle: small needle
atraumatic needle
Post-LP complaints
PLPH
1
11
III
II-2, III
2. ,4 LP attempts Back pain 11 II-2
3. Passive withdrawal Severe headache 1 II-2, III
4. Lateral recumbent position Post-LP complaints 1/2 III
5. Collection up to 30 mL Headache 1 II-2, III
Abbreviations: LP, lumbar puncture; INR, International normalized ratio; PLPH, postlumbar puncture headache; G, gauge.
NOTE. Grading the impact on risk factors:1 high (mentioned in multicenter LP feasibility study as one of the most important factors that influences post-LP
complications),1 high (mentioned in multicenter LP feasibility study as factor that influences post-LP complications or reported in other study with high qual-
ity evidence),1/2moderate (not detected as risk factor in multicenter LP feasibility study, based on consensus and literature),2 low (not detected as risk factor
in multicenter LP feasibility study, based on consensus and sparse literature). Level of evidence: II-2 5 well-designed cohorts preferably with more than one
research group or center (e.g., data of large multicenter LP feasibility study, systematic review); III5 consensus evidence based on clinical experience of the two
consortia (JPND BIOMARKAPD and BioMS).
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recumbent position due to the fact that the sitting posi-
tion was associated with more severe headache [5,36].
For CSF pressure measurement, patients need to be in
the lateral recumbent position.
 The collection of up to 30 mL of CSF is well tolerated
and safe [36].
As local anesthesia and bed rest after LP are not associ-
ated with increased prevalence of post-LP complications,
there are no recommendations to apply (level II-2 and III
evidence).
In conclusion, an LP is a common and generally well-
tolerated diagnostic procedure with a high diagnostic yield.
The application of these evidence-based guidelines will help
to reduce complication rates.Acknowledgments
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1. Systematic review: Consensus guidelines and recom-
mendations for the lumbar puncture (LP) procedure
to obtain cerebrospinal fluid (CSF) to minimize
risk of complications and to optimize diagnostic
yield are lacking. CSF analysis is increasingly rele-
vant for diagnosis and research for neurological dis-
eases, even at the core criteria for dementia
diagnosis.
2. Interpretation: It is recommended to use 25G atrau-
matic needles. A total of four LP attempts is an
acceptable maximum, active CSF withdrawals
should be avoided. It is advised to perform LP in
the lateral recumbent position, and collection up to
30-mL CSF is well tolerated and safe. There is no
recommendation to apply local anesthesia and bed
rest after the LP to reduce postpuncture complaints.
3. Future directions: The application of these evidence-
based guidelines will help to reduce complication
rates. Moreover, these guidelines will be a reference
for educational purposes, thus be of help for trainees
in neurology, and will be a guide to comfort or give
adequate information to the patients.
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